BSE Live
Jan 14, 16:01Prev. Close
173.35
Open Price
172.95
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Jan 14, 15:59Prev. Close
173.55
Open Price
172.69
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
172.45 (187)
| Profit & Loss account of Marksans Pharma (in Rs. Cr.) | Mar 10 | Mar 09 | Mar 08 | Mar 07 | Mar 06 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| INCOME | ||||||
| Revenue From Operations [Gross] | 199.56 | 203.79 | 243.26 | 239.89 | 291.85 | |
| Less: Excise/Sevice Tax/Other Levies | 1.81 | 4.03 | 6.52 | 10.28 | 7.49 | |
| Revenue From Operations [Net] | 197.75 | 199.76 | 236.75 | 229.61 | 284.37 | |
| Total Operating Revenues | 197.75 | 199.76 | 236.75 | 229.61 | 284.37 | |
| Other Income | 1.44 | 0.78 | 9.94 | 13.28 | 6.49 | |
| Total Revenue | 199.19 | 200.54 | 246.69 | 242.89 | 290.85 | |
| EXPENSES | ||||||
| Cost Of Materials Consumed | 40.05 | 34.32 | 51.67 | 83.62 | 55.19 | |
| Purchase Of Stock-In Trade | 100.08 | 116.42 | 132.62 | 130.62 | 179.94 | |
| Operating And Direct Expenses | 1.53 | 2.07 | 2.83 | 4.96 | 1.69 | |
| Changes In Inventories Of FG,WIP And Stock-In Trade | 11.98 | -10.60 | -15.10 | -40.68 | -23.55 | |
| Employee Benefit Expenses | 10.77 | 12.90 | 13.57 | 13.39 | 9.99 | |
| Finance Costs | 14.78 | 15.33 | 11.22 | 11.50 | 10.35 | |
| Depreciation And Amortisation Expenses | 9.84 | 9.73 | 8.59 | 7.32 | 8.04 | |
| Other Expenses | 9.26 | 17.57 | 21.19 | 21.75 | 17.25 | |
| Total Expenses | 198.56 | 198.34 | 227.42 | 233.33 | 259.53 | |
| Profit/Loss Before Exceptional, ExtraOrdinary Items And Tax | 0.63 | 2.20 | 19.27 | 9.56 | 31.32 | |
| Exceptional Items | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Profit/Loss Before Tax | 0.63 | 2.20 | 19.27 | 9.56 | 31.32 | |
| Tax Expenses-Continued Operations | ||||||
| Current Tax | 0.09 | 0.27 | 2.30 | 1.20 | 4.50 | |
| Less: MAT Credit Entitlement | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Deferred Tax | 0.25 | 1.24 | 1.51 | 2.81 | 3.54 | |
| Tax For Earlier Years | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Total Tax Expenses | 0.34 | 1.64 | 4.00 | 4.22 | 8.14 | |
| Profit/Loss After Tax And Before ExtraOrdinary Items | 0.29 | 0.56 | 15.27 | 5.34 | 23.18 | |
| Profit/Loss From Continuing Operations | 0.29 | 0.49 | 14.93 | 6.93 | 22.88 | |
| Profit/Loss For The Period | 0.29 | 0.49 | 14.93 | 6.93 | 22.88 | |
| OTHER ADDITIONAL INFORMATION | ||||||
| EARNINGS PER SHARE | ||||||
| Basic EPS (Rs.) | 0.01 | 0.01 | 0.42 | 1.93 | 6.37 | |
| Diluted EPS (Rs.) | 0.01 | 0.01 | 0.42 | 1.93 | 6.37 | |
| VALUE OF IMPORTED AND INDIGENIOUS RAW MATERIALS STORES, SPARES AND LOOSE TOOLS | ||||||
| Imported Raw Materials | 13.08 | 2.87 | 0.44 | 33.41 | 16.92 | |
| Indigenous Raw Materials | 21.28 | 24.53 | 0.56 | 38.76 | 29.62 | |
| STORES, SPARES AND LOOSE TOOLS | ||||||
| Imported Stores And Spares | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Indigenous Stores And Spares | 0.00 | 0.00 | 0.00 | 0.00 | 0.36 | |
| DIVIDEND AND DIVIDEND PERCENTAGE | ||||||
| Equity Share Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Tax On Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Equity Dividend Rate (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
26.11.2025
Marksans Pharma Consolidated September 2025 Net Sales at Rs 720.41 crore, up 12.23% Y-o-Y
24.11.2025
Marksans Pharma Standalone September 2025 Net Sales at Rs 320.44 crore, up 3.83% Y-o-Y
09.09.2025
Marksans Pharma Standalone June 2025 Net Sales at Rs 319.73 crore, up 25.62% Y-o-Y
20.05.2025
Marksans Pharma Consolidated March 2025 Net Sales at Rs 708.46 crore, up 26.51% Y-o-Y